ClinicalTrials.gg
Active, not recruitingNCT05457582SHAWNUpdated Jul 21, 2026

PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI

An interventional study of Placebo plus high-intensity statin and PCSK 9 Inhibitor plus high-intensity statin in Acute Coronary Syndrome, Hyperlipidemias and Percutaneous Coronary Intervention, sponsored by Nanjing First Hospital, Nanjing Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Acute Coronary Syndrome with a site in China — 55 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
44th of 115
1,212 · median 499
Started
2023
with 12 others
No phase
47 of 185
20 open now
Primary completion
2026-12
later than 30 of 62 live
Registered
124th of 185
by date

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 44th largest by planned enrollment of the 115 interventional ones that give a count, is one of 13 that started in 2023, is one of 47 with no phase, reaches primary completion later than 30 of the 62 other live ones, and was the 124th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

55 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

The primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, myocardial infarction, stroke, re-hospitalization due to acute coronary syndromes or heart failure, or any ischemia-driven coronary revascularization) in patients with acute coronary syndrome and multiple lesions. Alirocumab was used before June 10, 2025; Tafolecimab has been used from June 10, 2025 onward.

Read the detailed description

Patients with acute coronary syndrome (ACS) are at high-risk. ACS patients are commonly associated with multiple lesions or multivessel disease. Percutaneous coronary intervention (PCI) is an effective treatment for culprit lesions in ACS. Statin at high-intensity is recommended by current guidelines in order to prevent/slow the progression of non-culprit disease or restenosis. PCSK9 inhibitor serves as the most powerful medication in lowering LDL via promoting the expression of LDL receptors in the liver. However, if the combination of PCSK9 inhibitor with high-intensity statin treatment could significantly reduce the cardiovascular events in patients with ACS who underwent PCI remains unknown. Alirocumab was used before June 10, 2025; Tafolecimab has been used from June 10, 2025 onward.

03

Conditions studied

  • Acute Coronary Syndrome
  • Hyperlipidemias
  • Percutaneous Coronary Intervention
  • Cardiovascular Events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject, or their legal guardian, must have a clear understanding of the trial's design and treatment procedures. They must provide written before any trial-specific tests or procedures are conducted.
  2. Both male and female subjects aged ≥18 years.
  3. Subjects who have experienced an ACS and have undergone PCI for culprit lesions (either QFR or FFR \< 0.8) are eligible. ACS is defined as:

(1) Unstable angina (characterized by rest pain lasting between 5 and 30 minutes or worsening exertional angina accompanied by either transient ST segment depression or elevation, or angiography revealing visually estimated diameter stenosis of 90% or greater, or a ruptured plaque or thrombotic lesion), or (2) Non-ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and non-ST segment elevation, or (3) ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and ST-segment elevation.

4. Low-density lipoprotein cholesterol levels must meet the following criteria:

  1. Low-density lipoprotein cholesterol ≥70 mg/dL (≥1.8 mmol/L) in patients who have been on a stable high-intensity statin regimen for at least 4 weeks before enrollment.
  2. Low-density lipoprotein cholesterol ≥90 mg/dL (≥2.3 mmol/L) in patients who have been on a moderate or low-intensity statin regimen before enrollment.
  3. Low-density lipoprotein cholesterol ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on a stable statin regimen for at least 4 weeks before enrollment.

5. Subjects must have at least one culprit lesion for ACS in a major native coronary artery (diameter stenosis >70% with a QFR or FFR\<0.8), and have at least one non-culprit vessel disease (diameter stenosis ≤70% with a QFR or FFR ≥0.8).

Exclusion criteria

Exclusion Criteria:

  1. Fasting serum triglyceride levels exceeding 400 mg/dL (exceeding 4.52 mmol/L) before randomization.
  2. Coronary artery disease is located within a saphenous vein graft or an arterial graft.
  3. Residual diameter stenosis greater than 50% as determined by visual examination after percutaneous coronary intervention of the culprit lesion.
  4. TIMI (Thrombolysis in Myocardial Infarction) flow less than 3 in the culprit vessel after PCI.
  5. Unstable clinical status, characterized by hemodynamic (including cardiogenic shock) or electrical instability.
  6. Uncontrolled hypertension, indicated by multiple readings with systolic blood pressure (SBP) exceeding 180 mmHg or diastolic blood pressure (DBP) exceeding 110 mmHg.
  7. (NYHA) Class III or IV, and an already known (LVEF) below 30%.
  8. Known history of hemorrhagic stroke in last 180 days before randomization.
  9. Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response that has not been controlled by medications in the past 3 months before screening.
  10. Severe renal dysfunction, defined by an estimated (eGFR) below 30 ml/min/1.73m².
  11. Active liver disease or hepatic dysfunction.
  12. Known intolerance to rosuvastatin or any statin.
  13. Known allergy to contrast medium, heparin, aspirin, ticagrelor, prasugrel, or clopidogrel.
  14. Subjects who have previously received PCSK9 inhibitors.
  15. Subjects who have received cholesterol ester transfer protein inhibitors within the past 12 months before enrollment.
  16. Treatment with systemic or systemic cyclosporine within the past 3 months.
  17. Known active infection or major hematologic, metabolic, or endocrine dysfunction, as determined by the Investigator.
  18. Planned non-cardiac surgery within the next 12 months.
  19. Subjects who will not be able to attend the required study visits, as determined by the Investigator.
  20. Currently enrolled in another device or drug study.
  21. History of cancer within the past 5 years, unless adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer.
  22. Estimated of less than 12 months.
  23. Female of (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy, or hysterectomy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,212 participants (estimated)

Study arms

  • Placebo comparator
    Placebo plus high-intensity statin

    Participants received placebo subcutaneous injections once every 2 weeks (Q2W) plus high-intensity statin treatment (Rosuvastatin, 20 mg, once daily)

    Drug: Placebo plus high-intensity statin

  • Active comparator
    PCSK 9 Inhibitor plus high-intensity statin

    Participants received PCSK 9 Inhibitor Q2W subcutaneous injections

    Drug: PCSK 9 Inhibitor plus high-intensity statin

Interventions

  • DrugPlacebo plus high-intensity statin

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).

  • DrugPCSK 9 Inhibitor plus high-intensity statin

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).

06

What researchers measure

Primary outcomes

  1. Cardiovascular events

    Cardiovascular events defined as the composite of cardiovascular death, myocardial infarction, stroke or transit ischemic attack, re-hospitalization due to unstable angina or heart failure, or any ischemia-driven coronary revascularization.

    Time frame: 12 months after randomization

Secondary outcomes

  1. Cardiovascular death

    It will be adjudicated by an independent external CEC according to protocol defined definition.

    Time frame: 12 months after randomization

  2. All cause death

    It is defined as any death from randomization to the last visit.

    Time frame: 12 months after randomization

  3. Myocardial infarction

    It will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

  4. Stroke

    stroke will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

  5. Ischemia-driven coronary revascularization

    It will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

  6. Re-hospitalization due to unstable angina or heart failure

    It will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

  7. Diagnostic malignant tumor

    It will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

  8. PCSK9 inhibitors or statin intolerance

    It will be adjudicated by an independent external CEC.

    Time frame: 12 months after randomization

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 45 months is above that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Jul 14, 2022
StartActual
Mar 30, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2030
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05457582
Collaborators
National Natural Science Foundation of China, Nanjing Medical University
Responsible party
Shaoliang Chen, MD (Vice President of Nanjing First Hospital, Director of Cardiovascular Department, Nanjing First Hospital, Nanjing Medical University) — Principal investigator
First posted
Jul 14, 2022
Start date
Mar 30, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Jul 21, 2026

Study contacts

Shao-Liang Chen, MD, PhD
study chair · Nanjing First Hospital, Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion